pharmaphorum
JANUARY 28, 2021
It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients.
Express Pharma
NOVEMBER 1, 2024
Specific highlights of the budget for the sector include an increase in outlay for research and development and for the Ayushman BharatPradhan Mantri Jan Arogya Yojana (PM-JAY), the government’s universal health coverage scheme, which saw a 10 per cent budget increase to Rs 7,300 crores.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
MARCH 16, 2025
On the global stage, AI and Machine Learning (ML) drove drug discovery and process optimisation, especially as large-scale pharma companies adopted AI for precision medicine. Building sophisticated laboratories, recruiting scientific talent, and collaborating with global research institutions are essential steps in this process.
Express Pharma
SEPTEMBER 6, 2023
To help financially weak citizens gain access to affordable healthcare, the Pradhan Mantri Jan Arogya Yojana (PMJAY) was launched in 2018, providing about 500 million Indians with a ₹5 lakh family health insurance cover that include coverage for 1,400 medical procedures as well as critical diseases like prostate cancer.
Pharmaceutical Commerce
JUNE 17, 2025
Artificial intelligence addresses key limitations of traditional health technology assessments—such as data gaps and time-intensive processes—through automation, real-time data integration, and advanced predictive modeling, leading to faster and more informed decisions. In order to automate and enhance these tasks, AI-driven NLP can assist.
Pharma in Brief
FEBRUARY 2, 2022
In Canada, coverage for prescription drugs exists through an array of public and private drug plans. The Panel’s mandate did not include governance structures, financing, patient eligibility, or the interplay between public and private insurance plans. Background. a formulary); and. a formulary); and. Drug cost was not a consideration.
Big Molecule Watch
AUGUST 25, 2023
Congress left Medicare drug pricing to the drug manufacturers, pharmacies, and insurance plan sponsors to determine, and expressly prohibited the government from “interfering” in those private price negotiations under the so-called “Non-Interference Clause” of the Medicare Modernization Act of 2003.
Expert insights. Personalized for you.
119 
Let's personalize your content